



Effect of treatment modality on the long-term survival of patients with early glottic squamous cancer: a retrospective cohort study based on the SEER database

Wen-Lun Wang[#], Hong-Wei Zheng[#], Li-Hong Zhang, Li-Sheng Yu

Department of Otorhinolaryngology-Head and Neck Surgery, Peking University People's Hospital, Beijing, China

Contributions: (I) Conception and design: LS Yu, LH Zhang; (II) Administrative support: LS Yu, LH Zhang; (III) Provision of study materials or patients: WL Wang, HW Zheng; (IV) Collection and assembly of data: WL Wang, HW Zheng; (V) Data analysis and interpretation: WL Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Li-Hong Zhang, MD; Li-Sheng Yu, MD. Department of Otorhinolaryngology-Head and Neck Surgery, Peking University People's Hospital, Beijing, China. Email: lihongzhagent@163.com; lishengyu@163.com.

Background: The optimal treatment strategy for patients with early glottic (T1–2N0M0) squamous cancer remains unclear.

Methods: A retrospective population-based analysis was performed using the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was used to balance treatment arms, and Cox regression analysis was used to determine prognostic factors for survival. Kaplan-Meier analysis, log-rank tests, and competing risk analysis were used to compare survival outcomes between treatment modalities (surgery *vs.* radiotherapy).

Results: Among the 3,994 eligible patients in this study, surgery was associated with improved cancer-specific survival (CSS) and overall survival (OS) compared with radiotherapy (log-rank test, $P < 0.05$). This survival trend favoring surgery was consistent in the T1a, well/moderately differentiated grade, male, and all age subgroups. However, after the baseline characteristics were balanced with PSM, the survival outcomes (CSS and OS) did not differ significantly between the surgery and radiotherapy groups. Interestingly, surgery was associated with a 39% reduced risk of cancer-related death compared with radiotherapy in patients aged ≥ 70 years (hazard ratio 0.61; 95% CI: 0.43–0.87; $P = 0.006$). However, this survival trend favoring surgery was not observed in younger patients (age < 70 years), T stage subgroups, male or female subgroups, or in any of the pathological grade subgroups.

Conclusions: In patients with early glottic squamous cell carcinoma undergoing surgery or radiotherapy, there is no sufficient evidence favoring one method over another in terms of survival. However, surgery is recommended in patients aged ≥ 70 years because, in this group, it was associated with improved survival outcomes compared with radiotherapy.

Keywords: Glottic cancer; propensity score matching (PSM) study; Surveillance, Epidemiology, and End Results registry (SEER registry); radiotherapy; surgery

Submitted Oct 04, 2021. Accepted for publication Jan 14, 2022.

doi: 10.21037/atm-21-5288

View this article at: <https://dx.doi.org/10.21037/atm-21-5288>

Introduction

Laryngeal cancer is the second most common malignancy in the head and neck (1). It is estimated that, in 2021, there

will be approximately 12,620 new cases of laryngeal cancer and 3,770 deaths in the United States (2). Histologically, the vast majority of laryngeal cancers are squamous cell

carcinoma (SCC). Glottic cancer is the most common type of laryngeal cancer, accounting for approximately two-thirds of all laryngeal cancers (3). Because glottic cancer disturbs vocal function, these lesions are often diagnosed at an early stage. Survival for early glottic (T1T2N0M0) carcinoma is high, with a 5-year survival rate >90% (4).

The strategy for early glottic cancer is single-modality treatment (radiotherapy or surgery), highlighting the importance of larynx preservation and voice quality (5). Over the past two decades, transoral laser microsurgery (TLM) has supplanted open surgery as the mainstay surgical approach (6). Compared with open surgery, TLM has the advantages of being minimally invasive, lower cost, and associated with faster rehabilitation. If relapse occurs, salvage surgery or radiotherapy can be performed after the initial surgery. Typically, early stage glottic lesions are treated with a radiation dose of 50–70 Gy with 2–2.5 Gy/fraction. There is evidence that patients treated with radiotherapy have better voice quality than those treated with surgery (7). In recent years, intensity-modulated radiation therapy has become the most popular radiotherapy modality, with demonstrated superiority in reducing treatment-related toxicities.

Overall, given the lack of prospective randomized controlled trials, there is no sufficient evidence supporting one treatment method over another regarding oncological outcomes (8). Early glottic cancer is a heterogeneous disease. Tumors may exhibit different characteristics that make them appropriate for specific treatment methods. In addition, for a cancer with a high survival rate, a large sample size with long-term follow-up is necessary when treatment effects are evaluated. Consequently, the aims of the present study were to evaluate survival outcomes following surgery or radiotherapy in early glottic cancer and to identify patient-related characteristics associated with treatment effect by analyzing the Surveillance, Epidemiology, and End Results (SEER) database. We present the following article in accordance with the STROBE reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-5288/rc>).

Methods

Data collection

Data (2005–15) from the SEER program (Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub) was extracted for T1–2N0M0 glottic SCC. Briefly, data of patients

with primary site labeled “C32.0-Glottis”, behavior code “ICD-0–3=malignant”, and TNM sixth edition “(2004+)=T1–2N0M0” were included in the analysis. Patients were excluded if they met any of the following criteria: (I) they did not have SCC; (II) there was no pathological confirmation; (III) this was not the patients first primary cancer; (IV) if radiotherapy administered, it was not beam radiation; (V) patients were treated with both radiotherapy and surgery; and/or (VI) critical information, such as treatment modalities, TNM classification, or pathological grade, was missing. In this study, surgery included local tumor resection (with or without laser assistance), hemilaryngectomy, and total laryngectomy (with or without neck dissection). Radiotherapy included only external beam radiation. The present study was a cohort study, and patients were divided into 2 groups based on whether they received radiotherapy or surgery.

Demographic and clinical characteristics, including age (categorical variable; ≥ 70 and < 70 years), sex, race, marital status, diagnosis time (categorical variable), T stage, and pathological grade were collected from the database. “SEER disease-specific death classification” and “SEER other-cause death classification” codes were used to evaluate cancer-specific survival (CSS) and other cause-specific survival. Patients who were lost to follow-up or were still alive at the last follow-up were defined as censored.

This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Because SEER does not contain information that could identify patients, this study was deemed to be exempt from review by the institutional ethics committee of Peking University People's Hospital.

Statistical analysis

Because the patients were not randomly assigned in this retrospective study, the baseline covariates of the 2 groups might have been unbalanced which could have affected the evaluation of treatment results. Thus, propensity score matching (PSM) was used to minimize differences in baseline characteristics between the 2 groups with the “Nonrandom” R package. The propensity score (PS) of each patient was calculated with a logistic regression model that included the following variables: age, sex, race, insurance status, pathological grade, T stage, marital status, and diagnosis time. Each patient in the surgery group was matched 1:1 with a corresponding patient in the radiotherapy group using a nearest-neighbor PS matching algorithm with a caliper

Table 1 Demographic and clinical characteristics of the overall study cohort

Characteristics	No. of patients, n (%) n=3,994
Gender	
Male	3,573 (89.5)
Female	421 (10.5)
Age (years)	
49 and below	385 (9.6)
50–59	907 (22.7)
60–69	1,294 (32.4)
70–79	987 (24.7)
80 and over	421 (10.5)
Race	
White	3,363 (84.2)
Black	479 (12.0)
other	152 (3.8)
Marry status	
Married	2,622 (65.6)
Single	1,372 (34.4)
Insurance status	
Uninsured	22 (0.6)
Insured	718 (18.0)
unknown	3,154 (81.5)
Pathological Grade	
Well differentiated	1,200 (30.0)
Moderately differentiated	2,328 (58.3)
Poorly differentiated	448 (11.2)
undifferentiated	18 (0.5)
T stage	
T1a	2,026 (50.7)
T1b	382 (9.6)
T1nos	579 (14.5)
T2	1,007 (25.2)
Diagnosis time (years)	
2005–2009	1,031 (25.8)
2010–2015	2,963 (74.2)
Treatment modality	
Surgery	898 (22.5)
Radiotherapy	3,096 (77.5)

size of $\alpha=0.05$. A standardized difference value of $<10\%$ after matching was considered balanced.

Chi-square tests were used to compare baseline characteristics between the treatment groups before and after PSM. Kaplan-Meier analysis and log-rank tests were used to compare survival patterns between groups. According to a previous report (9), competing risk analysis was performed with other cause-specific death as a competing risk. Variables that were significant in univariate analysis at a level of $P<0.05$ were included in the multivariate analysis. Variables that are significant in clinical practice, such as diagnosis time, were also included (10). Cox regression analysis was performed to calculate adjusted hazard ratios (aHRs) of CSS and overall survival (OS) before and after PSM. A 2-sided P value <0.05 was considered statistically significant. All analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA) and R version 3.5.2 (The R Foundation for Statistical Computing, Vienna, Austria).

Results

Patient characteristics and survival analyses before PSM

In all, data for 3,994 patients satisfying the inclusion criteria were analyzed. The mean (\pm SD) patient age was 65 ± 11.4 years, and the median follow-up time was 86 months (interquartile range 51–127 months). Most patients were male (89.5%), married (65.6%), and White (84.2%). Just over half the patients were diagnosed with T1a disease (50.7%); 22.5% ($n=898$) underwent surgery and 77.5% ($n=3,096$) were treated with radiotherapy. The 5-year OS rate was 71.3% (95% CI: 69.9–72.7%), and the 5-year CSS rate was 84.8% (95% CI: 83.6–86%). Detailed information is provided in *Table 1*. There were more T2 patients in the radiotherapy than surgery group. Kaplan-Meier analysis (*Figure 1*) revealed that the 5-year CSS was significantly higher for patients in the surgery than in the radiotherapy group (89.5%, 95% CI: 87.3–91.6% *vs.* 83.4%, 95% CI: 82.0–84.7%; log-rank test $P<0.001$) as was 5-year OS (75.9%, 95% CI: 73.2–78.6% *vs.* 70%, 95% CI: 68.4–71.5%; log-rank test $P=0.001$). After stratification by T stage, age, pathological grade, and sex, surgery remained significantly associated with prolonged CSS in the T1a, well/moderately differentiated grade, male sex, and all age subgroups (*Figure S1*).

We also performed univariate survival analysis (*Table S1*) and further multivariate regression analysis in the overall cohort (*Table S2*). Age, sex, race, marital status, T stage, and




Figure 1 Survival analyses for patients with early glottic cancer before propensity score matching. (A) Overall survival and (B) cancer-specific survival for patients in the surgery and radiotherapy groups. Dashed and solid lines indicate survival rates, with shaded areas indicating 95% CIs.

treatment were identified as independent prognostic factors for OS in multivariate analysis. Patients undergoing surgery had a 13% reduced risk of death than did those receiving radiotherapy (aHR 0.87, 95% CI: 0.78–0.97; $P=0.015$). In addition, age, race, marital status, T stage, and treatment remained independent prognostic factors for CSS. Patients undergoing surgery had a 22% decreased risk of cancer-specific death than did those receiving radiotherapy (aHR 0.78, 95% CI: 0.65–0.94; $P=0.009$).

More survival analyses can be found in the supplementary.

Propensity score matching

Before further analysis, patients treated with surgery were matched with patients treated with radiotherapy based on their PS. As can be seen in *Table 2*, there were significant differences in demographic variables and clinical characteristics between the 2 treatment cohorts. The chi-square test indicated that patients treated with surgery had a better T stage ($P<0.001$), were more likely to be diagnosed between 2005 and 2009 ($P<0.001$), and were less likely to be Black ($P=0.004$). After matching, there was no statistically significant difference in covariates between the 2 groups ($P>0.05$). The absolute values of standardized differences in baseline variables were all $<10\%$ (*Figure 2*), suggesting that the variables between 2 comparator groups were well balanced after matching.

Patient characteristics and survival analyses after PSM

PSM generated 898 matched pairs of patients with early glottic cancer in the surgery and radiotherapy groups (*Table 2*). Kaplan-Meier analysis was performed to investigate the survival curves of the overall cohort. There was no significant difference in the 5-year OS between the surgery and radiotherapy groups (75.9%, 95% CI: 73.1–78.6% vs. 71.9%, 95% CI: 68.5–74.4%; log-rank test $P=0.21$; *Figure 3A*). In addition, there was no significant difference in the 5-year CSS between the surgery (89.5%, 95% CI: 87.4–91.6%) and radiotherapy groups (85.3%, 95% CI: 82.9–87.6%; log-rank test $P=0.13$; *Figure 3B*).

Univariate analysis was conducted to preliminarily screen prognostic factors for survival (*Table S3*). And then Cox regression analysis after PSM demonstrated that age, marital status, and T stage were independent risk predictors for OS and CSS (*Table 3*). However, treatment modality was not identified as an independent prognostic factor for OS (aHR 0.89, 95% CI: 0.78–1.02; $P=0.103$) or CSS (aHR 0.80, 95% CI: 0.64–1.00; $P=0.055$). Competing risk analysis revealed that both cancer-specific mortality and other causes of mortality were comparable between the surgery and radiotherapy groups (*Figure 3C*).

To explore whether the therapeutic effects of the 2 treatment modalities are consistent in patients with early glottic laryngeal cancer but with different clinical features, subgroup analyses were conducted (*Figure 4* and *Figure S2*).

Table 2 Patient characteristics stratified by treatment modalities before and after propensity score matching

Characteristics	Before PSM			After PSM		
	Surgery, n (%) n=898	Radiotherapy, n (%) n=3,096	P*value	Surgery, n (%) n=898	Radiotherapy, n (%) n=898	P* value
Insurance status			0.32			0.26
Uninsured	3 (0.3)	19 (0.6)		3 (0.3)	6 (0.7)	
Insured	160 (17.8)	558 (18.0)		160 (17.8)	150 (16.7)	
Unknown	735 (81.8)	2519 (81.3)		735 (81.8)	742 (82.6)	
Age (years)			0.291			0.83
49 and below	98 (10.9)	287 (9.3)		98 (10.9)	88 (9.8)	
50–59	198 (22.0)	709 (22.9)		198 (22.0)	211 (23.5)	
60–69	287 (32.0)	1007 (32.5)		287 (32.0)	295 (32.9)	
70–79	209 (23.3)	778 (25.1)		209 (23.3)	207 (23.1)	
80 and over	106 (11.8)	315 (10.2)		106 (11.8)	97 (10.8)	
Sex			0.088			0.29
Male	789 (87.9)	2,784 (89.9)		789 (87.9)	803 (89.4)	
Female	109 (12.1)	312 (10.1)		109 (12.1)	95 (10.6)	
Race			0.004			0.91
White	779 (86.7)	2,584 (83.5)		779 (86.7)	773 (86.1)	
Black	80 (8.9)	399 (12.9)		80 (8.9)	85 (9.5)	
other	39 (4.3)	113 (3.6)		39 (4.3)	40 (4.5)	
Pathological grade			0.309			0.73
Well differentiated	292 (32.5)	908 (29.3)		292 (32.5)	284 (31.6)	
Moderately differentiated	501 (55.8)	1827 (59.0)		501 (55.8)	517 (57.6)	
Poorly differentiated	101 (11.2)	347 (11.2)		101 (11.2)	91 (10.1)	
Undifferentiated	4 (0.4)	14 (0.5)		4 (0.4)	6 (0.7)	
T stage			<0.001			0.82
T1a	521 (58.0)	1,505 (48.6)		521 (58.0)	536 (59.7)	
T1b	69 (7.7)	313 (10.1)		69 (7.7)	60 (6.7)	
T1nos	143 (15.9)	436 (14.1)		143 (15.9)	141 (15.7)	
T2	165 (18.4)	842 (27.2)		165 (18.4)	161 (17.9)	
Marital status			0.524			0.58
Single	300 (33.4)	1,072 (34.6)		300 (33.4)	289 (32.2)	
Married	598 (66.6)	2,024 (65.4)		598 (66.6)	609 (67.8)	
Diagnosis time (year)			<0.001			0.80
2005–2009	304 (33.9)	727 (23.5)		304 (33.9)	299 (33.3)	
2010–2015	594 (66.1)	2,369 (76.5)		594 (66.1)	599 (66.7)	

*, Chi-square test. T1nos, T1 not specific; PSM, propensity score matching.




Figure 2 Comparison of standardized differences between patients undergoing surgery and receiving radiotherapy before and after propensity score matching. T1nos, T1 not specific.

In patients aged ≥ 70 years, surgery was associated with significantly improved survival compared with radiotherapy (5-year CSS 84.5%, 95% CI: 80.6–88.4% vs. 77.4%, 95% CI: 72.3–82.4%; $P=0.009$; *Figure 4B*). There was no significant difference in OS curves between the surgery and radiotherapy groups ($P=0.12$; *Figure 4C*). Competing risk analysis confirmed a tendency for a higher incidence of cancer-associated death among patients who received radiotherapy ($P=0.01$), with no significant difference in mortality due to other causes ($P=0.33$; *Figure 4D*).

We next performed univariate survival analysis (*Table S4*) and further multivariate survival analysis (*Table 4*) in patients aged ≥ 70 years after PSM. Multivariate survival analysis revealed that, in patients aged ≥ 70 years, age, T stage, and treatment modality were independent prognostic factors for CSS. For patients aged ≥ 70 years, the risk of death from cancer was significantly lower among patients undergoing surgery than among those receiving radiotherapy (aHR =0.61, 95% CI: 0.43–0.87; $P=0.006$). However, treatment modality was not an independent predictor of OS in this

subgroup of patients (aHR =0.85, 95% CI: 0.70–1.04; $P=0.118$). In patients aged <70 years, there were no significant differences in survival outcomes between the 2 treatment groups (*Figure 4A*). In addition, there were no significant differences in survival curves for the 2 treatment groups in the male/female, all T stage, or pathological grade subgroups (*Figure S2*).

Discussion

In the present study, we analyzed the survival of 3994 patients with early glottic SCC treated with surgery or radiotherapy. We found no clear evidence that a given treatment method was associated with improved survival in the overall cohort. However, surgery was associated with improved CSS in patients aged ≥ 70 years.

The demographic and clinical characteristics of this cohort are similar to those in previous studies (11–13). The mean (\pm SD) age of the present cohort was 65 ± 11.4 years, and the ratio of males to females was approximately 8.5:1.




Figure 3 Survival analyses for patients with early glottic cancer after propensity score matching. (A) Overall survival and (B) cancer-specific survival for patients in the surgery and radiotherapy groups. Dashed and solid lines indicate survival rates, with shaded areas indicating 95% confidence intervals. (C) Competing risk analysis for patients in the surgery and radiotherapy groups.

T1-stage disease accounted for 75% of the early stage glottic cancers, and most of the study cohort was White (84.3%). Not only may patient-related variables affect treatment choice, but there is increasing evidence that these variables also affect survival outcomes in patients with cancer (14,15). Chen *et al.* demonstrated that socioeconomic condition, insurance status, and race/ethnicity may affect treatment choice in patients with early stage laryngeal cancer (16). Another study of early-stage laryngeal cancer reported that patients treated with radiation therapy were more likely to be older and have a worse T stage (17). In the present study, patients treated with radiotherapy had a worse T stage, were more likely to be Black, and were more likely to have been recently diagnosed (2010–2015), suggesting a trend towards poor prognosis. Simple retrospective and population-based analyses may not be able to overcome these inherent biases in the different treatment arms. Consequently, PSM was used in the present study to balance the important patient-related characteristics. Our results indicate that the confounding factors in the 2 treatment arms were well balanced after matching.

To date, only 1 randomized controlled trial has compared open surgery with radiotherapy in terms of the oncological outcomes of early glottic cancer (18). In that study, there was no significant difference in 5-year disease-free survival in the overall cohort, but the open surgery strategy showed a survival benefit in patients with T2 stage disease. However, the conclusions in that study are limited because of potential bias and the small sample size. Many retrospective studies, systemic reviews, and meta-analyses have investigated oncological outcomes following open surgery versus radiotherapy for early glottic cancer. Higgins *et al.* showed higher OS for transoral surgery compared with radiotherapy in a meta-analysis of 7,600 patients with early glottic cancer (19). In a meta-analysis of more than 1000 patients with early glottic cancer, Guimarães *et al.* found a trend favoring transoral laser surgery with improved CSS, OS, and larynx preservation compared with radiotherapy (20). Patients with T2 stage diseases often have a more unfavorable prognosis than do those with T1 stage diseases, regardless of treatment option. A meta-analysis from Warner *et al.* examined the local control rate in 1,159 patients with T2 stage glottic cancer and found no difference between radiotherapy and surgery (21). To summarize, most of the recent literature favors surgery, as it shows slightly better survival outcomes compared to radiotherapy. However, these analyses were inherently biased by patient selection. Similar to previous reports (12,17), our analyses performed

Table 3 Multivariate survival analysis for patients with early glottic cancer after propensity score matching

Characteristic	Overall survival		Cancer-specific survival	
	aHR (95% CI)	P value	aHR (95% CI)	P value
Insurance status		0.184		0.83
Uninsured	Reference		Reference	
Insured	0.49 (0.15–1.57)		0.90 (1.12–6.67)	
Unknown	0.59 (0.19–1.87)		1.00 (1.14–7.29)	
Age		<0.001		<0.001
49 and below	Reference		Reference	
50–59	2.49 (1.65–3.77)		2.20 (1.20–4.01)	
60–69	4.32 (2.90–6.40)		3.18 (1.77–5.69)	
70–79	6.33 (4.26–9.39)		4.13 (2.29–7.45)	
80 and over	12.16 (8.09–18.26)	0.05	6.48 (3.48–1.20)	0.094
Sex: men vs. female	1.25 (1.00–1.57)		1.41 (0.94–2.12)	
Race		0.119		0.272
black	Reference		Reference	
White	0.95 (0.75–1.20)		0.77 (0.54–1.08)	
Other	0.67 (0.45–1.00)	<0.001	0.68 (0.37–1.25)	0.001
Marital status: married vs. single	0.68 (0.59–0.79)		0.68 (0.54–0.86)	
Grade		0.067		0.106
Well	Reference		Reference	
Moderately	1.07 (0.92–1.25)		1.20 (0.92–1.56)	
Poorly	1.37 (1.08–1.73)		1.60 (1.10–2.34)	
Undifferentiated	1.12 (0.53–2.38)		1.35 (0.42–4.30)	
T stage		<0.001		<0.001
T1a	Reference		Reference	
T1b	1.67 (1.33–2.11)		2.53 (1.78–3.61)	
T1nos	1.15 (0.94–1.41)		1.17 (0.82–1.68)	
T2	1.51 (1.27–1.81)		2.48 (1.89–3.24)	
Diagnosis time: 2005–2009 vs. 2010–2015	1.09 (0.93–1.27)	0.265	1.12 (0.95–1.33)	0.33
Treatment		0.103		0.055
Radiotherapy	Reference		Reference	
Surgery	0.89 (0.78–1.02)		0.80 (0.64–1.00)	

aHR, adjusted hazard ratio; T1nos, T1 not specific.




Figure 4 Survival analyses for patients with early glottic cancer stratified by age after propensity score matching. (A,B) Cancer-specific survival in patients aged <70 (A) and ≥70 years (B). (C) Overall survival in patients aged ≥70 years. Dashed and solid lines indicate survival rates, with shaded areas indicating 95% CIs. (D) Competing risk analysis for patients aged ≥70 years.

without PSM indicated that patients treated with surgery had better OS and CSS outcomes than did patients treated with radiotherapy. Furthermore, this survival trend favoring surgery was also evident in the T1a, male, well/moderately differentiated grade, and all age subgroups. Surgery seems to improve the survival of patients with early glottic cancer better than radiotherapy based on our preliminary analyses. However, after PSM, there was no significant difference in OS and CSS between the surgery and radiotherapy groups for patients with early glottic cancer. Further subgroup analyses stratified by T stage, sex, and pathological grade also revealed comparable survival outcomes between the 2 treatment methods.

The management of older adult patients with laryngeal cancer is complex. Although approximately 25% of head and neck cancers occur in patients aged ≥65 years (22), these patients are rarely enrolled in clinical trials. Older adult patients often have multiple comorbidities, poor

performance status, and a relatively low tolerance to treatment, restricting their suitability for aggressive treatment approaches. A meta-analysis by Bourhis *et al.* investigated the outcomes of head and neck cancer patients treated with hyperfractionated and accelerated radiotherapy (23). In that study, older adult patients were less likely to benefit from radiotherapy than were younger patients in terms of OS, cancer-related survival, and local control rate. Another large retrospective cohort study reported decreased CSS in older adult compared with younger patients after radiotherapy treatment (24). In contrast, many studies have analyzed the survival of older adult patients after surgery and demonstrated no significant effect of age on treatment efficacy (25,26). In the present study, cancer-related survival was significantly improved in older adult patients with early glottic cancer who underwent surgery compared with those who received radiotherapy. This superiority of surgery was not seen in

Table 4 Multivariate survival analysis for patients aged 70 years and older after propensity score matching

Characteristic	Overall survival		Cancer-specific survival	
	aHR (95% CI)	P value	aHR (95% CI)	P value
Age (years)		<0.001		0.016
70–80	Reference		Reference	
80 and above	1.90 (1.55–2.33)		1.55 (1.08–2.23)	
T stage		0.024		<0.001
T1a	Reference		Reference	
T1b	1.58 (1.14–2.18)		2.32 (1.37–3.92)	
T1nos	1.22 (0.91–1.63)		1.50 (0.90–2.49)	
T2	1.26 (0.95–1.67)		2.25 (1.45–3.49)	
Treatment		0.118		0.006
Radiotherapy	Reference		Reference	
Surgery	0.85 (0.70–1.04)		0.61 (0.43–0.87)	

Only variables with P value ≤ 0.05 were included in this table. aHR, adjusted hazard ratio; T1nos, T1 not specific.

younger patients. OS was similar between the 2 treatment methods in older adult patients. This may be due, in part, to most patients with laryngeal cancer dying from non-cancer-related diseases, the incidences of which did not differ significantly between the 2 treatment arms, as shown by our competing risk analyses.

Notably, 66.7% and 54.5% of the deaths of patients with stage I and stage II diseases, respectively, were not related to laryngeal carcinoma (27). One study reported that radiation increased the occurrence of cerebrovascular disease in laryngeal cancers (28), whereas another study indicated that radiotherapy was related to an increased risk of developing secondary cancers overall, especially head and neck cancers and lung cancer (29). In the present study, there was no significant difference in mortality from other causes in patients who received radiotherapy compared with those who underwent surgery. The results were the same for older adult patients, who may have a poorer performance status, more comorbidities, and a poorer tolerance to treatment. Radiotherapy is relatively safe in early glottic carcinoma, and this may be related to the smaller field of radiotherapy. The radiotherapy field for other head and neck cancers or advanced laryngeal cancers includes the bilateral elective cervical lymph nodes (30,31), whereas the radiotherapy field of early glottic cancer is limited to the laryngeal box (32). Currently, more advanced intensity-modulated radiation therapy technology allows for a reduced dose to

other important structures, such as the carotid artery (33). Because of the lack of detailed information about radiotherapy in the SEER database, we cannot further analyze which radiotherapy pattern is safe and effective.

This study has several limitations. First, there was an inherent patient selection bias in retrospective studies. Patients in the surgery group had a better T stage, were more likely to be diagnosed between 2005 and 2009, and were less likely to be Black, which might have led to a better prognosis. Despite improvements in methods balancing the baseline covariates, bias could not be completely overcome considering that a number of variables significantly related to survival, such as comorbidities and performance status, were not available from the database. Second, detailed information, such as the radiotherapy regimen and whether the surgery performed was TLM or open surgery, was not provided in the database. Currently, TLM has largely replaced open surgery in early-stage laryngeal cancer due to its minimal invasiveness. Many studies have demonstrated similar OS and local control rates between the 2 methods for early laryngeal cancer (34,35). However, open surgery may be better for lesions with deep infiltration (35). In the present study, both open surgery and TLM were categorized as part of the single “surgery” group. It would have been more meaningful if the analysis had been performed comparing just TLM and radiotherapy. In addition, T2b lesions have poorer local control rates

and survival outcomes compared with general T2-stage diseases (21). The lack of detailed data regarding tumor characteristics and treatment regimens hampers our further research on this topic. Thus, high-quality randomized controlled trials are still needed to validate our results.

Conclusions

In conclusion, this study has demonstrated that, in patients with early glottic SCC, there is no sufficient evidence favoring surgery over radiotherapy in terms of survival. However, patients aged ≥ 70 years might benefit from surgery with improved CSS. Yet, considering the inherent limitations of our retrospective study, randomized clinical trials with more rigorous criteria and specialized populations are still needed for a solid conclusion.

Acknowledgments

Funding: This work was supported by the National Natural Science Foundation of China (No. 82071034).

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-21-5288/rc>

Peer Review File: Available at <https://atm.amegroups.com/article/view/10.21037/atm-21-5288/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-5288/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with

the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. *Otolaryngol Clin North Am* 2008;41:673-95, v.
2. SEER Cancer Stat Facts: Laryngeal Cancer. National Cancer Institute. Bethesda, MD, USA. [Accessed April 2021]. Available online: <https://seer.cancer.gov/statfacts/html/laryn.html>
3. Ermiş E, Teo M, Dyker KE, et al. Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions. *Radiat Oncol* 2015;10:203.
4. Breda E, Catarino R, Monteiro E. Transoral laser microsurgery for laryngeal carcinoma: Survival analysis in a hospital-based population. *Head Neck* 2015;37:1181-6.
5. Baird BJ, Sung CK, Beadle BM, et al. Treatment of early-stage laryngeal cancer: A comparison of treatment options. *Oral Oncol* 2018;87:8-16.
6. Silver CE, Beitler JJ, Shaha AR, et al. Current trends in initial management of laryngeal cancer: the declining use of open surgery. *Eur Arch Otorhinolaryngol* 2009;266:1333-52.
7. Aaltonen LM, Rautiainen N, Sellman J, et al. Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy. *Int J Radiat Oncol Biol Phys* 2014;90:255-60.
8. Warner L, Chudasama J, Kelly CG, et al. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. *Cochrane Database Syst Rev* 2014;(12):CD002027.
9. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. *Bone Marrow Transplant* 2007;40:381-7.
10. Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. *Arch Otolaryngol Head Neck Surg* 2008;134:370-9.
11. Jones AS, Fish B, Fenton JE, et al. The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation? *Head Neck* 2004;26:127-35.
12. Brady JS, Marchiano E, Kam D, et al. Survival Impact of Initial Therapy in Patients with T1-T2 Glottic Squamous Cell Carcinoma. *Otolaryngol Head Neck Surg* 2016;155:257-64.

13. Remmelts AJ, Hoebbers FJ, Klop WM, et al. Evaluation of lasersurgery and radiotherapy as treatment modalities in early stage laryngeal carcinoma: tumour outcome and quality of voice. *Eur Arch Otorhinolaryngol* 2013;270:2079-87.
14. Lebo NL, Khalil D, Balram A, et al. Influence of Socioeconomic Status on Stage at Presentation of Laryngeal Cancer in the United States. *Otolaryngol Head Neck Surg* 2019;161:800-6.
15. Chen JJ, Stessin A, Christos P, et al. Differences in survival outcome between stage I and stage II glottic cancer: A SEER-based analysis. *Laryngoscope* 2015;125:2093-8.
16. Chen AY, Fedewa S, Zhu J. Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985-2007. *Arch Otolaryngol Head Neck Surg* 2011;137:1017-24.
17. Zhan C, Yang X, Song X, et al. Radiotherapy vs surgery for T1-2N0M0 laryngeal squamous cell carcinoma: A population-based and propensity score matching study. *Cancer Med* 2018. [Epub ahead of print].
18. Ogol'tsova ES, Paches AI, Matiakin EG, et al. Comparative evaluation of the effectiveness of radiotherapy, surgery and combined treatment of stage I-II laryngeal cancer (T1-2NoMo) based on the data of a cooperative randomized study. *Vestn Otorinolaringol* 1990;(3):3-7.
19. Higgins KM, Shah MD, Ogaick MJ, et al. Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy. *J Otolaryngol Head Neck Surg* 2009;38:603-12.
20. Guimarães AV, Dedivitis RA, Matos LL, et al. Comparison between transoral laser surgery and radiotherapy in the treatment of early glottic cancer: A systematic review and meta-analysis. *Sci Rep* 2018;8:11900.
21. Warner L, Lee K, Homer JJ. Transoral laser microsurgery versus radiotherapy for T2 glottic squamous cell carcinoma: a systematic review of local control outcomes. *Clin Otolaryngol* 2017;42:629-36.
22. Muir CS, Fraumeni JF Jr, Doll R. The interpretation of time trends. *Cancer Surv* 1994;19-20:5-21.
23. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. *Lancet* 2006;368:843-54.
24. Huang SH, O'Sullivan B, Waldron J, et al. Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. *Int J Radiat Oncol Biol Phys* 2011;79:46-51.
25. Kowalski LP, Alcantara PS, Magrin J, et al. A case-control study on complications and survival in elderly patients undergoing major head and neck surgery. *Am J Surg* 1994;168:485-90.
26. Morgan RF, Hirata RM, Jaques DA, et al. Head and neck surgery in the aged. *Am J Surg* 1982;144:449-51.
27. Ferlito A, Haigentz M Jr, Bradley PJ, et al. Causes of death of patients with laryngeal cancer. *Eur Arch Otorhinolaryngol* 2014;271:425-34.
28. Swisher-McClure S, Mitra N, Lin A, et al. Risk of fatal cerebrovascular accidents after external beam radiation therapy for early-stage glottic laryngeal cancer. *Head Neck* 2014;36:611-6.
29. Gao X, Fisher SG, Mohideen N, et al. Second primary cancers in patients with laryngeal cancer: a population-based study. *Int J Radiat Oncol Biol Phys* 2003;56:427-35.
30. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 2003;349:2091-8.
31. Tao Y, Auperin A, Blanchard P, et al. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial. *Radiother Oncol* 2020;150:18-25.
32. Gujral DM, Long M, Roe JW, et al. Standardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer. *Clin Oncol (R Coll Radiol)* 2017;29:42-50.
33. Berwouts D, Swimberghe M, Duprez F, et al. Intensity-modulated radiotherapy for early-stage glottic cancer. *Head Neck* 2016;38 Suppl 1:E179-84.
34. Jacobi C, Freundorfer R, Reiter M. Transoral laser microsurgery in early glottic cancer involving the anterior commissure. *Eur Arch Otorhinolaryngol* 2019;276:837-45.
35. Luo C, Lv K, Liu Q, et al. Comparison of laser microsurgery and open partial laryngectomy for T1-2 laryngeal cancer treatment. *Ann Transl Med* 2021;9:464.

Cite this article as: Wang WL, Zheng HW, Zhang LH, Yu LS. Effect of treatment modality on the long-term survival of patients with early glottic squamous cancer: a retrospective cohort study based on the SEER database. *Ann Transl Med* 2022;10(8):440. doi: 10.21037/atm-21-5288




Figure S1 Subgroup analyses of cancer-specific survival for patients with early glottic cancer before propensity score matching according to (A-C) T stage, (D,E) age, (F,G) pathological grade, and (H,I) sex. Dashed and solid lines indicate survival rates, with shaded areas indicating 95% CIs.




Figure S2 Survival analyses for patients with early glottic cancer stratified by (A-C) T stage, (D,E) pathological grade, and (F,G) sex after propensity score matching. Dashed and solid lines indicate survival rates, with shaded areas indicating 95% CIs.

Table S1 Univariate survival analysis for patients with early glottic cancer before propensity scores matching

Characteristic	Overall survival		Cancer-specific survival	
	HR (95% CI)	P value	HR (95% CI)	P value
Insurance status		0.67		0.61
Uninsured	Reference		Reference	
Insured	0.96 (0.45–2.05)	0.926	0.64 (0.26–1.57)	0.335
Unknown	1.03 (0.49–2.17)	0.937	0.68 (0.28–1.65)	0.395
Age		<0.001		<0.001
49 and below	Reference		Reference	
50–59	1.70 (1.33–2.18)	<0.001	1.46 (1.05–2.05)	0.023
60–69	2.91 (2.31–3.67)	<0.001	2.13 (1.56–2.91)	<0.001
70–79	4.31 (3.42–5.43)	<0.001	2.46 (1.78–3.38)	<0.001
80 and over	8.29 (6.50–10.6)	<0.001	3.72 (2.62–5.27)	<0.001
Sex: men vs. female	1.20 (1.03–1.39)	0.017	1.25 (0.98–1.59)	0.06
Race		0.079		0.005
Black	Reference		Reference	
White	0.94 (0.82–1.07)	0.359	0.71 (0.59–0.87)	0.001
Other	0.74 (0.56–0.97)	0.029	0.73 (0.49–1.07)	0.106
Marital status: married vs. single	0.71 (0.65–0.78)	<0.001	0.69 (0.60–0.79)	<0.001
Pathological grade		0.005		0.004
Well	Reference		Reference	
Moderately	1.08 (0.98–1.20)	0.10	1.23 (1.04–1.44)	0.015
Poorly	1.27 (1.09–1.48)	0.002	1.51 (1.20–1.91)	0.001
Undifferentiated	1.79 (1.03–3.11)	0.038	1.82 (0.75–4.42)	0.187
T stage		<0.001		<0.001
T1a	Reference		Reference	
T1b	1.53 (1.32–1.76)	<0.001	2.23 (1.79–2.76)	<0.001
T1nos	1.02 (0.88–1.78)	0.786	1.08 (0.85–1.37)	0.534
T2	1.50 (1.35–1.67)	<0.001	2.33 (1.98–2.73)	<0.001
Diagnosis time: 2005–2009 vs. 2010–2015	1.03 (0.93–1.14)	0.56	1.17 (0.99–1.37)	0.06
Treatment		0.001		<0.001
Radiotherapy	Reference		Reference	
Surgery	0.84 (0.75–0.93)	0.001	0.72 (0.60–0.86)	<0.001

AHR, adjusted hazard ratio.

Table S2 Multivariate survival analysis for patients with early glottic cancer before propensity scores matching

Characteristic	Overall survival		Cancer-specific survival	
	AHR (95% CI)	P value	AHR (95% CI)	P value
Insurance status				
Uninsured	Reference	0.231	Reference	0.306
Insured	0.62 (0.29–1.32)		0.53 (0.22–1.31)	
Unknown	0.69 (0.32–1.45)		0.58 (0.24–1.42)	
Age				
49 and below	Reference	<0.001	Reference	<0.001
50–59	1.68 (1.31–2.15)		1.42 (1.03–2.00)	
60–69	2.95 (2.34–3.71)		2.14 (1.56–2.93)	
70–79	4.44 (3.52–5.60)		2.58 (1.87–3.56)	
80 and over	8.63 (6.76–11.0)		3.97 (2.80–5.64)	
Sex: men vs. female	1.26 (1.08–1.48)	0.002	1.26 (0.98–1.61)	0.065
Race				
Black	Reference	0.017	Reference	0.022
White	0.89 (0.78–1.02)		0.76 (0.62–0.92)	
Other	0.67 (0.51–0.88)		0.75 (0.51–0.91)	
Marital status: married vs. single	0.71 (0.65–0.78)	<0.001	0.72 (0.62–0.83)	<0.001
Pathological grade				
Well	Reference	0.286	Reference	0.207
Moderately	1.01 (0.92–1.12)		1.09 (0.92–1.28)	
Poorly	1.15 (0.98–1.13)		1.28 (1.01–1.62)	
Undifferentiated	1.19 (0.68–2.06)		1.30 (0.53–3.17)	
T stage				
T1a	Reference	<0.001	Reference	<0.001
T1b	1.43 (1.24–1.65)		2.06 (1.65–2.56)	
T1nos	1.04 (0.90–1.20)		1.08 (0.85–1.37)	
T2	1.55 (1.39–1.72)		2.27 (1.93–2.67)	
Diagnosis time: 2005–2009 vs. 2010–2015	1.01 (0.90–1.12)	0.859	1.11 (0.94–1.31)	0.20
Treatment				
Radiotherapy	Reference	0.015	Reference	0.009
Surgery	0.87 (0.78–0.97)		0.78 (0.65–0.94)	

AHR, adjusted hazard ratio.

Table S3 Univariate survival analysis for patients with early glottic cancer after propensity scores matching

Characteristic	Overall survival		Cancer-specific survival	
	AHR (95% CI)	P value	AHR (95% CI)	P value
Insurance status		0.475		0.998
Uninsured	Reference		Reference	
Insured	0.71 (0.22–2.23)	0.553	1.03 (0.12–7.50)	0.975
Unknown	0.81 (0.26–2.51)	0.710	1.02 (0.14–7.29)	0.983
Age		<0.001		<0.001
49 and below	Reference		Reference	
50–59	2.54 (1.69–3.83)	<0.001	2.44 (1.33–4.45)	0.004
60–69	4.30 (2.91–6.34)	<0.001	3.36 (1.89–5.98)	<0.001
70–79	6.17 (4.17–9.14)	<0.001	4.04 (2.45–7.27)	<0.001
80 and over	11.6 (7.72–17.3)	<0.001	6.44 (3.48–11.9)	<0.001
Sex: men vs. female	1.19 (0.95–1.48)	0.11	1.43 (0.96–2.12)	0.06
Race		0.30		0.06
black	Reference		Reference	
white	0.87 (0.70–1.09)	0.252	0.65 (0.47–0.91)	0.01
Other	0.74 (0.50–1.10)	0.138	0.68 (0.38–1.24)	0.21
Marital status: married vs. single	0.73 (0.64–0.84)	<0.001	0.72 (0.57–0.90)	0.005
Pathological grade		0.04		0.02
well	Reference		Reference	
moderately	1.11 (0.95–1.29)	0.174	1.32 (1.01–1.71)	0.038
Poorly	1.36 (1.08–1.71)	0.009	1.71 (1.18–2.49)	0.004
Undifferentiated	1.83 (0.86–3.88)	0.114	2.29 (0.72–7.25)	0.159
T stage		<0.001		<0.001
T1a	Reference		Reference	
T1b	1.83 (1.45–2.30)	<0.001	2.69 (1.89–3.83)	<0.001
T1nos	1.03 (0.84–1.26)	0.774	1.12 (0.78–1.59)	0.529
T2	1.45 (1.22–1.73)	<0.001	2.46 (1.89–3.21)	<0.001
Diagnosis time: 2005–2009 vs. 2010–2015	1.07 (0.92–1.24)	0.371	1.43 (1.11–1.84)	0.005
Treatment		0.21		0.126
Radiotherapy	Reference		Reference	
Surgery	0.92 (0.80–1.05)	0.21	0.84 (0.67–1.05)	0.126

AHR, adjusted hazard ratio.

Table S4 Univariate survival analysis for patients aged 70 years and older with early glottic cancer after propensity scores matching

Characteristic	Overall survival		Cancer-specific survival	
	AHR (95% CI)	P value	AHR (95% CI)	P value
Insurance status	1.27 (0.93–1.75)	0.126	0.89 (0.56–1.42)	0.64
Unknown vs. insured				
Age				
80 and over vs. 70–79	1.90 (1.55–2.32)	<0.001	1.56 (1.09–2.23)	0.015
Sex: men vs. female	1.08 (0.80–1.47)	0.596	0.98 (0.59–1.64)	0.95
Race		0.435		0.378
Black	Reference		Reference	
White	1.06 (0.74–1.52)	0.735	0.68 (0.40–1.17)	0.166
Other	0.79 (0.44–1.41)	0.424	0.84 (0.36–1.98)	0.692
Marital status: married vs. single	0.76 (0.62–0.94)	0.01	0.75 (0.53–1.07)	0.12
Pathological grade		0.63		0.44
well	Reference		Reference	
moderately	1.02 (0.83–1.27)	0.829	1.35 (0.91–2.00)	0.132
Poorly	1.18 (0.83–1.67)	0.345	1.34 (0.71–2.52)	0.371
Undifferentiated	1.54 (0.68–3.50)	0.297	1.83 (0.44–7.58)	0.401
T stage		0.05		0.001
T1a	Reference		Reference	
T1b	1.55 (1.12–2.14)	0.009	2.26 (1.34–3.82)	0.002
T1nos	1.16 (0.87–1.55)	0.304	1.45 (0.87–2.40)	0.147
T2	1.21 (0.92–1.61)	0.176	2.15 (1.40–3.34)	0.001
Diagnosis time: 2005–2009 vs. 2010–2015	1.05 (0.85–1.30)	0.62	1.45 (0.98–2.12)	0.06
Treatment		0.123		0.009
Radiotherapy	Reference		Reference	
Surgery	0.86 (0.71–1.04)	0.123	0.63 (0.45–0.89)	0.009

AHR, adjusted hazard ratio.